Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer

Abstract Background Treatment with regorafenib, a multiple-kinase inhibitor, to manage metastatic colorectal cancers (mCRCs) shows a modest improvement in overall survival but is associated with severe toxicities. Thus, to reduce regorafenib-induced toxicity, we used regorafenib at low concentration...

Full description

Bibliographic Details

Published in:	Journal of Experimental & Clinical Cancer Research
Main Authors:	Prachi Bajpai, Sumit Agarwal, Farrukh Afaq, Sameer Al Diffalha, Darshan S. Chandrashekar, Hyung-Gyoon Kim, Abigail Shelton, C. Ryan Miller, Santosh K. Singh, Rajesh Singh, Sooryanarayana Varambally, Ganji Purnachandra Nagaraju, Ashish Manne, Ravi Paluri, Moh’d Khushman, Upender Manne
Format:	Article
Language:	English
Published:	BMC 2024-07-01
Subjects:	Colorectal cancer JAK/HDACi Regorafenib Combination therapy Toxicity
Online Access:	https://doi.org/10.1186/s13046-024-03106-8